Video summary

Inhalers (Asthma Treatment & COPD Treatment) Explained!

Main summary

Key takeaways

Educational

Main ideas & concepts

  • Inhalers treat airway narrowing by targeting receptors on bronchial smooth muscle

    • The airway (bronchus) has smooth muscle that controls the diameter (lumen).
    • If smooth muscle contracts, the lumen gets smaller → worsened breathing.

  • Two key smooth-muscle receptors

    • Muscarinic receptor (M) → causes smooth muscle contraction
    • Beta receptor (β) → relaxes smooth muscle

  • Therapeutic strategy based on receptor effects

    • Use muscarinic inhibitors (antagonists) to block contraction
    • Use beta agonists to activate relaxation → bronchodilation

  • Inhaled corticosteroids (ICS)

    • Reduces inflammation (not tied to the receptor mechanism described for M and β)

  • Three core drug classes for bronchi

    1. Muscarinic antagonists
    2. Beta agonists
    3. Inhaled corticosteroids

How to identify drug classes by name endings (methodology)

  • Muscarinic antagonists

    • Common endings: -ium
    • Examples: tiotropium, ipratropium, umeclidinium
    • Also commonly grouped with this: -late
    • Example: glycopyrrolate

  • Beta agonists

    • Ending: -ol
    • Examples: formoterol, salmeterol, albuterol

  • Inhaled corticosteroids

    • Ending: -one
    • Examples: fluticasone, mometasone

Clinical treatment framework (as described): step-up/step-down by rescue inhaler use

Common baseline for both asthma and COPD

  • Everyone with either asthma or COPD uses a short-acting beta agonist (SABA) as a rescue inhaler.

  • Defined shorthand:

    • SABA = short-acting beta agonist (examples given: ProAir, Ventolin, albuterol)
    • LABA = long-acting beta agonist
    • Long-acting muscarinic antagonists (examples given: tiotropium, umeclidinium, glycopyrrolate)
    • ICS = inhaled corticosteroid

Asthma: escalation/de-escalation rules

(described as a “ramping up or ramping down” based on rescue inhaler frequency)

  1. Start with ICS
  2. Check rescue inhaler (SABA) use frequency
    • 1–2 times per week:
      • No escalation (ICS alone is considered adequate)
    • 3+ times per week:
      • Add LABA
    • If SABA use stays 3+ times per week even after adding ICS + LABA:
      • Add a long-acting muscarinic antagonist (LAMA)
  3. De-escalation
    • If SABA use is 0 times per week (“very well controlled”):
      • Can drop the LAMA if the patient was on it
      • If the patient is essentially on ICS alone, you can also drop LABA and keep ICS

Key asthma constraint noted

  • You should not use a LABA without first using an ICS.

COPD: escalation pattern

(also described using initial choices and then escalation based on symptoms/rescue use)

  1. Start with a long-acting muscarinic antagonist (LAMA)
    • Examples: tiotropium, umeclidinium, glycopyrrolate
  2. Then reassess SABA use
    • If SABA use is 3+ times per week, then add LABA
  3. ICS position in COPD
    • The talk emphasizes that ICS is typically used last in COPD (i.e., not among the first additions in their general sequence)

Combination inhalers: how to infer drug class from what’s inside

  • Rationale: Many patients require more than one medication, so combination inhalers are common.

  • COPD combinations

    • Often LAMA + LABA
    • Rule of thumb given:
      • Look for one component ending in -ium (LAMA) and one ending in -ol (LABA)
    • Example: vilanterol + umeclidinium → LAMA/LABA

  • Asthma combinations

    • Often ICS + LABA
    • Example: fluticasone + salmeterol → ICS/LABA (e.g., “Advair”)

  • Also stated

    • LABA alone exists but is becoming rarer in practice:
      • Asthma: LABA usually paired with ICS
      • COPD: LABA usually paired with LAMA

Exception / clinical nuance mentioned (asthma dose adjustment)

  • In asthma, if stepping down or if an ICS increase/de-escalation doesn’t work as expected, the standard plan may be modified.
  • One specific exception described:
    • If a patient has atrial fibrillation and adding a LABA might increase heart rate, instead of adding a LABA:
      • Increase the dose/potency of ICS (low → medium → high), and/or
      • Consider adding a leukotriene receptor antagonist (mentioned as type 4 in the corner, not fully integrated into the main framework)

Speakers / sources featured

  • MedCram lecture (video speaker not explicitly named in the subtitles)

Original video